SCHEMBL4765411

SCHEMBL4765411

CCCCOc1ccc2ccccc2c1-c1[c]nns1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KCNH2 Q12809 3/20 0.43
CNR1 P21554 3/20 0.42
CNR2 P34972 3/20 0.42
ALOX5 P09917 1/20 0.40
HTR1B P28222 2/20 0.40
CYP2C9 P11712 1/20 0.39
HTR1D P28221 1/20 0.38
MCHR1 Q99705 1/20 0.38
TLR8 Q9NR97 1/20 0.38
MEN1 O00255 1/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.37
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722242 0.94 MEN1 (0.43) GAATDP1L3MBTL1KCNH2CNR1
SCHEMBL4723532 0.89 ALOX5 (0.51) GAATDP1ALOX5CYP2C9MEN1
SCHEMBL4721049 0.82 MAPT (0.58) CYP2C9MEN1KMT2AMAPT
SCHEMBL14331323 0.80 GAA (0.65) GAATDP1L3MBTL1KCNH2CNR1
SCHEMBL4722853 0.78 GAA (0.50) GAATDP1L3MBTL1KCNH2CNR1
SCHEMBL4720100 0.78 GAA (0.50) GAATDP1L3MBTL1KCNH2CNR1
SCHEMBL4723651 0.77 CYP1A2 (0.48) CNR2CYP2C9MCHR1TLR8
SCHEMBL8881796 0.75 GAA (0.59) GAATDP1L3MBTL1KCNH2CNR1
SCHEMBL24891589 0.73 KCNH2 (0.54) GAATDP1L3MBTL1KCNH2CNR1
SCHEMBL2048172 0.72 MAPT (0.58) GAATDP1L3MBTL1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 GAA 3876/4885TDP1 1332/4885L3MBTL1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.